Mannitol versus hypertonic saline for brain relaxation in patients undergoing craniotomy – A Cochrane Systematic Review

Hemanshu Prabhakar, Gyaninder P. Singh, Mani Kalaivani, Vidhu Anand

Abstract

Background: Patients with brain tumour usually suffer from increased pressure in the skull due to swelling of brain tissue. A swollen brain renders surgical removal of the brain tumour difficult. To ease surgical tumour removal, measures are taken to reduce brain swelling, often referred to as brain relaxation. Brain relaxation can be achieved with intravenous fluids such as mannitol or hypertonic saline. The objective of this review was to compare the effects of mannitol versus those of hypertonic saline on intraoperative brain relaxation in patients undergoing craniotomy.

Methods: We searched the Cochrane Central Register of Controlled Trials (2013, Issue 10), MEDLINE through OvidSP (1966 to October 2013) and EMBASE through OvidSP (1980 to October 2013). We also searched specific websites, such as www.indmed.nic.in, www.cochrane-sadcct.org and www.clinicaltrials.gov. We included randomised controlled trials (RCTs) that compared the use of hypertonic saline versus mannitol for brain relaxation. We also included studies in which any other method used for intraoperative brain relaxation was compared with mannitol or hypertonic saline. The primary outcomes were longest follow-up mortality, Glasgow outcome scale score at 3 months and any adverse event related to mannitol or hypertonic saline. The secondary outcomes were intraoperative brain relaxation, Intensive Care Unit (ICU) stay, hospital stay and quality of life. We used standardised methods for conducting a systematic review as described by the Cochrane Handbook for Systematic Reviews of Interventions. Two review authors independently extracted details of trial methodology and outcome data from reports of all trials considered eligible for inclusion. All analyses were made on an intention-to-treat basis. We used a fixed-effect model when no evidence was found of significant heterogeneity between studies and a random-effects model when heterogeneity was likely.

Results: We included six RCTs with 527 participants. Only one RCT was judged to be at low risk of bias. The remaining five RCTs were at unclear or high risk of bias. No trial mentioned the primary outcomes of longest follow-up mortality, Glasgow outcome scale score at 3 months or any adverse event related to mannitol or hypertonic saline. Three trials mentioned that the secondary outcomes of intraoperative brain relaxation, hospital stay, ICU stay and quality of life were not reported in any of the trials. Brain relaxation was inadequate in 42 of 197 participants in the hypertonic saline group and 68 of 190 participants in the mannitol group. The risk ratio for brain bulge or tense brain in the hypertonic saline group was 0.60 (95% confidence interval 0.44–0.83, low-quality evidence). One trial reported ICU and hospital stay.

Access this article online

Quick Response Code: www.jnaccjournal.org

DOI: 10.4103/jnacc.jnacc_8_17

mean (standard deviation [SD]) duration of ICU stay in the mannitol and hypertonic saline groups was 1.28 (0.5) and 1.25 (0.5) days (P = 0.64), respectively; the mean (SD) duration of hospital stay in the mannitol and hypertonic saline groups was 5.7 (0.7) and 5.7 (0.8) days (P = 1.00), respectively. **Conclusions:** From the limited data available on the use of mannitol and hypertonic saline for brain relaxation during craniotomy, it is suggested that hypertonic saline significantly reduces the risk of tense brain during craniotomy. A single trial suggests that ICU stay and hospital stay are comparable with the use of mannitol or hypertonic saline. However, focus on other related important issues such as long-term mortality, long-term outcome, adverse events and quality of life is needed.

**Key words:** Brain relaxation, craniotomy, hypertonic saline, mannitol

**INTRODUCTION**

One of the important goals of anaesthetic management for patients undergoing craniotomy is to provide a relaxed brain on which the surgeon can operate. This allows easy surgical manipulation and causes less damage to normal brain tissue. This, in turn, results in less secondary injury to the brain, which improves the patient’s neurological outcome. Raised intracranial pressure results in a tense brain during the intraoperative period. Administration of mannitol is generally considered to be a ‘gold standard’ for the treatment of raised intracranial pressure. Hypertonic saline is another intravenous fluid that has effects comparable with those of mannitol in terms of reduction in intracranial pressure.[1-3] Earlier works on the use of hypertonic saline in neurosurgical patients have shown promising results.[4-5]

Raised intracranial pressure during the intraoperative period results in bulging of brain and poor surgical exposure. Various treatment methods have been used by anaesthetists to reduce this intraoperative brain bulge. These methods include hyperventilation (increasing respiratory rate); drainage of cerebrospinal fluid; use of intravenous anaesthetic agents such as propofol and thiopentone; facilitation of venous drainage by positioning of patients with head up and use of osmotic agents, such as mannitol and hypertonic saline. These manoeuvres facilitate relaxation of the brain and surgery as less retraction pressure is required to separate the lobes of the brain.

Mannitol is a six-carbon sugar with a molecular weight of 182; it is available as 20% and 25% solution. Mannitol is rapidly infused intravenously in doses of 0.25–1 g/kg. As it is hyperosmolar, that is, has greater osmolality than blood, mannitol facilitates the shift of water from the brain into the vasculature. Hypertonic saline is the hyperosmolar solution of normal saline, which is a sodium chloride solution. It is commonly available in concentrations of 3%, 5%, 7.5% and 23%. Hypertonic saline provides the advantage of not crossing the blood–brain barrier; therefore, it remains in the intravascular compartment and does not enter into brain tissue.[6] Hypertonic saline has less of diuretic effect when compared with mannitol and thus maintains better cerebral perfusion pressure.[6] Osmotic diuretics such as mannitol and hypertonic saline increase the osmolality of the blood, which shifts water from the brain to the intravascular compartment, that is, into the blood. Intravenous administration of hypertonic saline has been shown to improve cerebral perfusion. At the same time, brain oedema is reduced by the intervention, thus increasing compliance and decreasing intracerebral pressure. Hyperosmolar solutions such as mannitol and hypertonic saline have been used routinely to achieve brain relaxation in neurosurgical patients undergoing craniotomy. Both agents offer advantages and disadvantages. Through this review, we sought to identify which of the two agents are better suited to intraoperative brain relaxation. The objective of this review was to compare the effects of mannitol versus those of hypertonic saline on intraoperative brain relaxation in patients undergoing craniotomy.

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**
We included randomised controlled trials (RCTs) that compared the use of hypertonic saline versus mannitol for brain relaxation. We also included studies in which any other method used for intraoperative brain relaxation was compared with mannitol or hypertonic saline.

We excluded studies in which other methods for producing brain relaxation such as hyperventilation and administration of drugs such as furosemide had not been uniformly used between two study groups. Monitoring of intracranial pressure was not a prerequisite for inclusion of studies in our review.

**Types of participants**
We included paediatric and adult participants (>18 years of age) of either gender who received mannitol or hypertonic saline during craniotomy for brain tumour. We excluded neonates (younger than 28 days old) from this review.

**Types of interventions**
The experimental intervention was hypertonic saline and the control treatment was mannitol.
Types of outcome measures
Primary outcomes
1. Longest follow-up mortality
2. Outcome at 3 months (Glasgow outcome scale score)
3. Adverse events such as electrolyte imbalance, haemodynamic disturbance, rebound oedema and kidney injury.

Secondary outcomes
1. Brain relaxation (as assessed on three-, four- or five-point scales and reported as dichotomised outcomes: good and poor)
2. Intensive Care Unit (ICU) stay
3. Hospital stay

Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Trials (2013, Issue 10) [Appendix 1], MEDLINE through OvidSP (1966 to October 2013) [Appendix 2] and EMBASE through OvidSP (1980 to October 2013) [Appendix 3].

The MEDLINE search strategy was adapted for searches of other databases. We applied no language restrictions.

Searching other resources
We searched for relevant ongoing trials on specific websites such as the following.
1. www.indmed.nic.in
2. www.cochrane-sadcct.org

Data collection and analysis
Selection of studies
Using results of the above searches, we screened all titles and abstracts for eligibility. Two review authors (Gyaninder P Singh and Vidhu Anand) independently performed this screening. We obtained and assessed for relevance of the full articles for all the potentially eligible RCTs relevance based on the preplanned checklist. Each review author documented the reason for exclusion of each excluded trial. We resolved disagreements between review authors through discussion with the third review author (Hemanshu Prabhakar), who decided on inclusion or exclusion of the study. We compiled a list of all eligible trials.

Data extraction and management
Two review authors (Gyaninder P Singh and Vidhu Anand) independently extracted the data and assessed trial quality using a standardised data extraction form. We resolved disagreements through consultation with the third review author (Hemanshu Prabhakar). In cases in which additional information was required, Gyaninder P Singh or Hemanshu Prabhakar contacted the first author of the relevant trial.

Assessment of risk of bias in included studies
Two review authors independently assessed the methodological quality of the included trials (Vidhu Anand and Gyaninder P Singh). We resolved disagreements through discussion with the third review author (Hemanshu Prabhakar). We performed the assessment as suggested in the Cochrane Handbook for Systematic Reviews of Interventions[8] and judged the risk of bias of included studies on the basis of the following domains.
1. Random sequence generation
2. Allocation concealment
3. Blinding and outcome
4. Incomplete outcome reporting
5. Publication bias and any other bias
6. Follow-up of study participants.

We considered a trial as having low risk of bias if all domains were assessed as adequate. We considered a trial as having high risk of bias if one or more domains were assessed as inadequate or unclear. We included a ‘risk of bias’ table as part of the characteristics of included studies and a ‘risk of bias summary’ figure, which detailed all judgements made for all the studies included in the review.

Measures of treatment effect
We undertook statistical analysis using the statistical software, Review Manager 5.2.,[9] of the Cochrane Collaboration. We used risk ratios (RRs) to measure treatment effect for proportions (dichotomous outcomes) among primary outcomes and adverse effects. We converted continuous data to mean differences (MDs) using the inverse variance method and we calculated an overall MD. We used a fixed-effect model when no evidence of significant heterogeneity was found between studies, and a random-effects model when heterogeneity was likely.[10] As an estimate of the statistical significance of a difference between experimental and control interventions, we calculated RRs and MDs between groups as well as 95% confidence intervals (CIs). A statistically significant difference between intervention and control groups was assumed if 95% CI did not include the value of no differential effect.

Unit of analysis issues
We included in our review only RCTs with a parallel group design.
Dealing with missing data
We performed quantitative analysis on an intention-to-treat basis and contacted study authors to obtain missing data. We analysed missing data, if any, by imputation using best- and worst-case scenario methods. If we found insufficient data, the potential impact of the missing data was considered in the interpretation of results.

Assessment of heterogeneity
We did not perform meta-analysis if we suspected important clinical heterogeneity on examination of the included trials. We used the Q-statistic to test statistical heterogeneity between trials and considered a $P \leq 0.05$ as indicating significant heterogeneity; the $I^2$ statistic was used to assess the magnitude of heterogeneity.[11] We considered $I^2 > 50\%$ to indicate that a meta-analysis was not appropriate and used a random-effects model analysis if $I^2$ was between 30\% and 50\%. However, the decision to use a random- or fixed-effect model did not rest solely on the value of $I^2$ but rather was based on an overall assessment of the heterogeneity of included studies. When in doubt, we carried out both fixed- and random-effects models to examine potential differences.

Assessment of reporting biases
We assessed publication bias, funding bias and small-study effect in a qualitative manner, using a funnel plot. We planned to test for funnel plot asymmetry if >10 studies were included in the meta-analysis.

Data synthesis
We quantitatively reviewed the included data and combined them by intervention, outcome and population, using Review Manager 5.2.[9] We synthesised data in the absence of important clinical or statistical heterogeneity and expressed RRs for proportions.

Subgroup analysis and investigation of heterogeneity
When appropriate, given obvious clinical or statistical ($I^2 > 40\%$) heterogeneity, we considered subgroup analysis based on the age of participants (children vs. adults) and on concentrations of hypertonic saline and mannitol. We considered doses of hypertonic saline and mannitol in subgroup analyses if the data indicated heterogeneity on that basis.

Sensitivity analysis
We performed sensitivity analysis to explore the consistency of effect size measures in trials with low risk of bias versus high risk of bias and to investigate the impact of missing data using the imputation method described above.

Summary of findings
We planned to use the principles of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system[12] in our review to assess the quality of the body of evidence associated with specific outcomes (mortality, outcome at 3 months, brain relaxation, ICU stay, hospital stay and adverse effects) and to construct a ‘summary of findings’ (SoF) table using GRADEpro software. The GRADE approach appraises the quality of a body of evidence based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Assessment of the quality of a body of evidence considers within-study risk of bias (methodological quality), directness of the evidence, heterogeneity of the data, precision of effect estimates and risk of publication bias. We created the SoF [Figure 1] for brain relaxation. We found low evidence recommending the use of hypertonic saline for intraoperative brain relaxation in patients undergoing surgery for brain tumour, therefore, use of hypertonic saline rather than mannitol is recommended.
RESULTS

Description of studies

Included studies
We included six studies in our review [Figure 1]. All included studies were of parallel design, and only three studies used equiosmolar concentrations of fluids. None of the included studies reported our primary outcomes. Brain bulk was reported differently by all of the studies; however, appropriate data were not provided by the authors of three studies. A single study reported our secondary outcomes of the ICU stay and hospital stay.

Excluded studies
We excluded seven studies; two studies were not RCTs. We were unable to obtain the full text for three studies. A probable duplication of data was noted in one study and in another study, the participant population and the clinical setting were different from those in our inclusion criteria.

Risk of bias in included studies
We assessed the risk of bias of included studies using the ‘risk of bias’ tool developed by the Cochrane Collaboration. The risk of bias tool invites judgements on five items for each trial (selection bias, performance bias, detection bias, attrition bias and reporting bias). All review authors independently assessed risk of bias for each study and resolved disagreements by discussion. The characteristics of included studies used for our assessment of the risk of bias in included studies are shown in Figures 2 and 3. Only one study was found to be of high methodological quality.

Allocation (selection bias)
Of the six included studies, only three reported allocation concealment. The remaining studies did not describe allocation concealment.

Blinding (performance bias and detection bias)
Of the six included studies, only three reported blinding of participants and personnel; four studies reported blinding of the outcome assessor. The remaining studies did not describe blinding.

Incomplete outcome data (attrition bias)
Five studies reported data on all participants. However, this information remained unclear in one study as it was presented as an abstract and study authors failed to include it.

Selective reporting (reporting bias)
We found that all planned outcomes were reported in the studies. The study authors reported all outcomes mentioned in their methodology.

Other potential sources of bias
We could find no other potential sources of bias in four of the included studies. In one study, the intervention fluid was donated by a pharmaceutical company and this could have introduced bias into the study. The source of the intervention fluid remained unclear in another study.

Effects of interventions

Primary outcomes
Longest follow-up mortality
No study reported this outcome.

Outcome at 3 months (Glasgow Outcome Scale score)
No study reported this outcome.
Adverse events such as electrolyte imbalance, haemodynamic disturbance, rebound oedema and kidney injury
No study reported these outcomes.

None of the studies reported our primary outcomes of longest follow-up mortality, Glasgow outcome scale score at 3 months and adverse events such as electrolyte imbalance, haemodynamic disturbance, rebound oedema and kidney injury.

**Secondary outcomes**
**Brain relaxation**
Three studies enrolling 387 participants reported brain relaxation (73.4% of total participants in this review). These three trials suggest that the incidence of inadequate brain relaxation was reduced from 68 of 190 in the mannitol group to 42 of 197 in the hypertonic saline group (RR of brain bulge 0.60, 95% CI - 0.44–0.83, \( P = 0.002 \)). No heterogeneity was noted in these studies [Figure 4].

**Intensive Care Unit and hospital stay**
Only one study enrolling 238 participants reported the ICU stay and hospital stay (45.2% of total participants in this review). This study suggested that the mean (standard deviation [SD]) duration of ICU stay in the mannitol and hypertonic saline groups was 1.28 (0.5) and 1.25 (0.5) days (\( P = 0.64 \)), respectively; the mean (SD) duration of hospital stay in the mannitol and hypertonic saline groups was 5.7 (0.7) and 5.7 (0.8) days (\( P = 1.00 \)), respectively.

**Quality of life assessment**
No study reported this outcome.

**DISCUSSION**

This review concerns randomised evidence for the use of hypertonic saline and mannitol in patients undergoing surgery for brain tumour. We planned to collect data on clinically relevant outcomes such as mortality, outcome at 3 months and adverse events (primary), along with other parameters (secondary outcomes) such as intraoperative brain relaxation, length of ICU and hospital stay and quality of life. Data on the primary end points of our review were lacking. However, we were able to collect data for the incidence of intraoperative brain relaxation in study participants receiving two fluids.

None of the studies reported our primary outcomes. Only three studies reported our secondary outcomes. Our analysis suggests that hypertonic saline is beneficial in producing brain relaxation in patients undergoing surgery for brain tumour. Length of ICU stay and length of hospital stay were comparable after intraoperative use of hypertonic saline or mannitol.

The overall methodological quality of these studies cannot be considered good, but no heterogeneity was noted. However, this evidence was obtained from a limited number of studies. We were unable to retrieve data on many clinically useful outcomes such as mortality, outcome at 3 months and quality of life. The evidence produced by this review, therefore, should be interpreted with caution, keeping in mind that it is only intraoperative brain relaxation that may be achieved more effectively with the use of hypertonic saline.

We selected randomised studies for our review, and most of these studies did not report details of randomisation and allocation concealment. However, blinding was carried out in most. The overall methodological quality of these studies could not be considered good. The included studies had homogeneous populations, and no heterogeneity was noted. For brain relaxation, the quality of evidence was low as suggested by the SoF [Table 1].

In an attempt to minimise bias, we followed the guidelines provided in the Cochrane Handbook for...
Implications for practice
The finding of our review that hypertonic saline causes brain relaxation more effectively than mannitol was derived from a limited number of studies. Therefore, the authors of this review cannot draw firm conclusions on the benefits of any one fluid over another for use during the intraoperative period as far as brain relaxation is concerned.

Implications for research
The finding from this review is based on only two well-reported studies; therefore, the results should be interpreted with caution. RCTs based on uniform and standard methodology are needed. Proper methods of randomisation and blinding should be followed. Standard doses of mannitol and hypertonic saline, administered at a specified intraoperative time, should be important considerations in the RCT. It is imperative that patient-related outcomes such as mortality, quality of life, outcome at 3 months or 1 year and ICU and hospital stay should be considered while the study is being designed. RCTs should be adequately powered. A multi-centre trial involving centres in different parts of the world would probably be useful.

Acknowledgements
We would like to thank Arash Afshari (content editor), Cathal Walsh (statistical editor) and Peter JD Andrews, Robert Wyllie, Federico Bilotta and Rainer Lenhardt (peer reviewers) for help and editorial advice provided during preparation of this systematic review. We would also like to thank Jane Cracknell (Managing Editor, Cochrane Anaesthesia Review Group [CARG]) for guiding us through this protocol and Karen Hovhanissyan (Trials Search Co-ordinator, CARG) for preparing our search strategy.

Table 1: Summary of findings
Mannitol versus hypertonic saline for brain relaxation in patients undergoing craniotomy

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No. of participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inadequate brain relaxation</td>
<td>Mannitol</td>
<td>358 per 1000</td>
<td>RR 0.6 (0.44 to 0.83)</td>
<td>387 (3 studies)</td>
<td>⊕⊕⊝⊝ lowb</td>
</tr>
<tr>
<td>3- or 4-point scalesa</td>
<td>Hypertonic saline</td>
<td>215 per 1000 (157 to 297)</td>
<td>Moderate</td>
<td>181 per 1000 (133 to 251)</td>
<td></td>
</tr>
</tbody>
</table>

*The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio.

GRADE Working Group grades of evidence.
**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.
**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
**Very low quality:** We are very uncertain about the estimate.

*a- or 4-point scales were used by study authors to assess brain relaxation. b-Downgraded two levels owing to serious concerns about allocation, blinding and potential sources of other bias noted in the included studies.

CONCLUSIONS

Systematic Reviews of Interventions. Eligibility for inclusion and exclusion and assessment of risk of bias of different studies were performed independently by two review authors.

We are unaware of any such review that compares hypertonic saline and mannitol in patients undergoing surgery for brain tumour.

We would like to thank Arash Afshari (content editor), Cathal Walsh (statistical editor) and Peter JD Andrews, Robert Wyllie, Federico Bilotta and Rainer Lenhardt (peer reviewers) for help and editorial advice provided during preparation of this systematic review. We would also like to thank Jane Cracknell (Managing Editor, Cochrane Anaesthesia Review Group [CARG]) for guiding us through this protocol and Karen Hovhanissyan (Trials Search Co-ordinator, CARG) for preparing our search strategy.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.
REFERENCES


APPENDICES

Appendix 1: Cochrane Central Register of Controlled Trials search strategy

#1 MeSH descriptor Mannitol explode all trees
#2 mannitol*
#3 (#1 OR #2)
#4 MeSH descriptor Craniotomy explode all trees
#5 MeSH descriptor Neurosurgical Procedures explode all trees
#6 MeSH descriptor Neurosurgery explode all trees
#7 MeSH descriptor Intracranial Pressure explode all trees
#8 MeSH descriptor Intraoperative Period explode all trees
#9 (brain near (surg* or manipulat* or procedure* or relax*)) or craniotom* or (neurosurg* near (patient* or procedure* or manipulat*)) or (intracranial near pressure)
#10 (#4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 (#3 AND #10)
Appendix 2: MEDLINE (Ovid SP) search strategy

1. exp Mannitol/or mannitol*.af.
2. exp Craniotomy/or Neurosurgical Procedures/or Neurosurgery/or Intracranial Pressure/or Intraoperative Period/or (brain adj3 (surg* or manipulat* or procedur* or relax*)).mp. or craniotom*.af. or (neurosurg* adj3 (patient* or procedur* or manipulat*)).mp. or (intracranial adj3 pressure).mp.
3. 1 and 2
4. (((randomised controlled trial or controlled clinical trial).pt. or randomised.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or trial.ab. or groups.ab.) not (animals not (humans and animals))).sh.
5. 3 and 4

Appendix 3: EMBASE (Ovid SP) search strategy

1. exp mannitol/or mannitol*.af.
2. exp craniotomy/or neurosurgery/or intracranial pressure/or intraoperative period/or (brain adj3 (surg* or manipulat* or procedur* or relax*)).mp. or craniotom*.af. or (neurosurg* adj3 (patient* or procedur* or manipulat*)).mp. or (intracranial adj3 pressure).mp.
3. ((randomised-controlled-trial/or randomisation/or controlled-study/or multicenter-study/or phase-3-clinical-trial/or phase-4-clinical-trial/or double-blind-procedure/or single-blind-procedure/or (random* or cross?over* or multicenter* or factorial* or placebo* or volunteer*).mp. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti, ab. or (latin adj square).mp.) not (animals not (humans and animals))).sh.
4. 1 and 2 and 3